Week of February 22st, 2021 | Vol. 10, Issue 8
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse

Project Bulldog
Sell-side | Pharma Services| Life sciences consulting firm
Eurofins Scientific, a leader in bioanalytical testing, has acquired Beacon Discovery, a preeminent drug discovery and contract research organization (CRO) focused on G-Protein Coupled Receptor (GPCR) research.
Beacon Discovery joins Eurofins Discovery, a CRO with a broad portfolio of validated in vitro pharmacology, ADMET, and chemistry services for integrated drug discovery solutions. The transaction is expected to close in the coming weeks upon fulfilment of customary closing conditions.
Eurofins acquired Beacon Discovery for its innovative approach, years of experience in drug discovery and development as well as its expertise in GPCR research, complemented by its unique compound library. The addition of Beacon Discovery supports Eurofins’ strategy to be the partner of choice to the pharmaceutical industry, providing drug discovery experience, knowledge, and proven success in supporting the discovery and development of new therapeutics.

An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
14 transactions totaling $1,344 million
Supplies, Equipment & Services
20 transactions totaling $335 million
Healthcare IT & Managed Care
6 transactions totaling $183 million
Healthcare Facilities & Distributors
8 transactions totaling $44 million
Pharma & Biotech
25 transactions totaling $892 million
Supplies, Equipment & Services
15 transactions totaling $117 million
Healthcare IT & Managed Care
17 transactions totaling $568 million
Healthcare Facilities & Distributors
2 transactions totaling $5 million
Pharma & Biotech
15 transactions totaling $842 million
Supplies, Equipment & Services
10 transactions totaling $2,669 million
Healthcare IT & Managed Care
2 transactions totaling $404 million
Healthcare Facilities & Distributors
2 transactions totaling $59 million
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
February 19, 2021 - Fierce Pharma
The drug giant is opening a “global capability hub” in the city, bringing multiple services—including finance, human resources, digital and sourcing—to one office. The company will lease more than 100,000 square feet and hire 50 employees, the Tampa Bay Times reports

February 19, 2021 - Fierce Pharma
The AMR Action Fund has raised another $140 million to support antibiotic development. The cash adds to the almost $1 billion committed by around 20 biopharma companies, giving the fund the means to work toward its goal of helping up to four antibiotics to market by the end of the decade. 

February 18, 2021 - Fierce Pharma
Novavax on Thursday unveiled a memorandum of understanding with Gavi, the Vaccine Alliance, to provide 1.1 billion doses of its coronavirus vaccine candidate to COVAX, a global effort to ensure equitable vaccine distribution. The Serum Institute of India will help produce doses under a prior deal between that company and Gavi.

February 17, 2021 - Contract Pharma
Charles River Laboratories has signed an agreement to acquire Cognate BioServices, a cell and gene therapy contract development and manufacturing organization (CDMO), for approximately $875 million. The deal is expected to close by the end of the first quarter of 2021.
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.